Summary
45 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $548.6M against $143.9M.
- Analysts expect revenue to grow by 49% this fiscal year.
What to watch
- It earns only 6.3 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveToday you pay 142.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 49%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 29 USD
- Research and development 15 USD
- Sales and administration 45 USD
- Taxes and other 2.5 USD
- Net profit 8.4 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 8.4 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 4.3 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $126 is 19% above today's price. 75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.